Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1906 to 1920 of 9044 results

  1. Abatacept for treating active idiopathic inflammatory myopathies [TSID10095]

    Awaiting development Reference number: GID-TA10993 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Primary hyperparathyroidism

    Awaiting development Reference number: GID-QS10089 Expected publication date: TBC

    Quality standard
    Awaiting development

  3. Pancreatitis (including acute pancreatitis)

    Awaiting development Reference number: GID-QS10085 Expected publication date: TBC

    Quality standard
    Awaiting development

  4. Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years [ID6484]

    Awaiting development Reference number: GID-TA11632 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Alpha-1 antitrypsin for treating high-risk acute graft-versus-host disease after a haematopoietic stem cell transplant in people 12 years and over [ID6664]

    Awaiting development Reference number: GID-TA11596 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation [ID6460]

    Awaiting development Reference number: GID-TA11534 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Point-of-care lipid tests for cardiovascular disease prevention in primary and community care

    Awaiting development Reference number: GID-HTG10528 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  8. Allo-APZ2-EB for treating dystrophic and junctional epidermolysis bullosa in people of any age [ID6746]

    Awaiting development Reference number: GID-TA11980 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Itopride hydrochloride for treating gastrointestinal symptoms of functional dyspepsia [ID6745]

    Awaiting development Reference number: GID-TA11979 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Fenfluramine for treating seizures caused by CDKL5 deficiency disorder in people 1 year and over [ID6740]

    Awaiting development Reference number: GID-TA11966 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. AK-OTOF for treating hearing loss caused by otoferlin gene variants [ID6735]

    Awaiting development Reference number: GID-TA11962 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions

    Awaiting development Reference number: GID-HTG10170 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  13. Levodopa/carbidopa (ND0612) for Parkinson's Disease [ID6727]

    Awaiting development Reference number: GID-TA11954 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Allo-APZ2-CVU for treating chronic venous leg ulcers [ID6754]

    Awaiting development Reference number: GID-TA11988 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. High Definition – transcranial Electrical Stimulation (HD-tES) for fibromyalgia

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation